Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
about
Genomic diversity of colorectal cancer: Changing landscape and emerging targetsAdvances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal CancerMolecular testing to optimize therapeutic decision making in advanced colorectal cancerBiomarkers predicting resistance to epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer with wild-type KRASA Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal CancerPrecision medicine in colorectal cancer: the molecular profile alters treatment strategiesNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Management of colorectal cancerThe role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trialsTreatment of metastatic colorectal cancer: focus on panitumumabHow to select the optimal treatment for first line metastatic colorectal cancerMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerEGFR Overexpressed in Colonic Neoplasia Can be Detected on Wide-Field Endoscopic Imaging.Beyond RAS and BRAF: a target rich disease that is ripe for pickingRole of targeted therapy in metastatic colorectal cancerTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceMechanisms of resistance to anti-EGFR therapy in colorectal cancerRAS and BRAF in metastatic colorectal cancer managementMechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancerSecond-line systemic therapy for metastatic colorectal cancer.Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available dataA feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?EZH2 expression is a prognostic biomarker in patients with colorectal cancer treated with anti-EGFR therapeutics.DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancerFCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review.Current approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patientsModeling RAS phenotype in colorectal cancer uncovers novel molecular traits of RAS dependency and improves prediction of response to targeted agents in patientsIncidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysisMetastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.A molecular signature for the prediction of recurrence in colorectal cancer.Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.Expanded RAS: refining the patient populationRisk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials.Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer.Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.Predictive Modeling of Drug Treatment in the Area of Personalized Medicine.Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients.Metastatic Colorectal Cancer: A Systematic Review of the Value of Current Therapies.
P2860
Q26739052-DBBAB7FB-4AF2-42EA-8FDB-912495F2E6FFQ26748924-359DC7D1-DA15-4FD0-8CBE-339F7E419644Q26749012-BFE0E027-12BE-42A5-86E5-F0376835F1B7Q26766535-C50CA319-70AC-4D32-8260-DFD3FE3638C9Q26775711-1E73E826-411D-44E7-A85B-76D0D54E02A8Q26795558-911B8655-6E6D-4FB2-AF7A-1F08BB21DA96Q26796348-DB7525F7-C856-4BB7-A5F1-FB5676D85BF5Q26823550-E841BD43-5395-4192-B4D0-B79E4B9D18ADQ26858892-5E9BE815-EDB5-46F7-8719-A755B2C42173Q27022954-5EE07E28-3996-450D-90E4-964C27F2E775Q27026516-F2BA1F14-9582-41DC-BBD9-6F7EF38C4B72Q27027648-B549AD9F-1279-49D6-87D7-26D89EBF18D8Q27325591-64A5C70C-A893-4C02-97D6-FC9FC430A233Q28066095-18EC8BFE-6335-4B81-9FA2-B89637C2364DQ28068817-8CC50F83-9A5B-49F9-9001-FD664771CDACQ28071772-04646BB9-756A-4D0F-9256-1DE6E9CB38F2Q28074073-5ECCC275-20A8-4EB9-924D-E668C9597600Q28074175-68BB853D-12E6-4B34-8CFE-B0471A9220F2Q28076490-A309BE54-ACB0-40FB-9125-5FCC826604ADQ30238760-FCEFAA59-21B4-4615-A664-4417D6F463CBQ30862367-4267A8AB-C781-4EFF-9935-190D02CAF4A9Q33555283-2E285BD5-A1CF-4860-AF79-3BE6A6767264Q33566687-956E0CCF-881B-4752-98E4-D4CBBFA7B872Q33679684-C5352809-3FB2-48DE-AA41-6BE2D89012D9Q33712230-F2E5AA5C-1575-4B77-9217-23424110C73CQ33732199-0D6CBF75-37F9-4B93-BF57-EDF8C7A53EA3Q33861210-35F089CC-2756-459B-B06C-296EE87496A7Q34078212-924D1710-DEFE-4757-8212-3547D80D868FQ34537664-95E94EB9-D686-4589-9FAD-7FBF14E16D41Q34664272-AB823C6A-8B36-4855-855A-39895C6EA20AQ35060617-E27E6ED0-2D4D-47C4-B9EB-056F7B28F2E9Q35067570-59B5A887-B8C5-41EE-9A74-F0AEE2247696Q35102475-A7E2D2E6-0E83-44EF-AEBF-3EF4071E2C7EQ35211367-4260488F-EC0D-4C86-BEB4-5E6968DD3356Q35746635-D45D4BD7-703E-410A-AB5C-B4DDF8DFDB75Q35754399-63EA8A0A-F06F-4181-B113-85F99EEE4301Q36115580-AA8DAC62-ED02-45CF-BFDD-BDC8887CBF07Q36351777-2D1CBB23-DCE2-4190-B06B-C744B1FF27B1Q36544641-471272FD-3389-4D5A-ADF1-957DCDAA72A3Q36553713-1D792882-C142-4F21-BC46-5939E4355B71
P2860
Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Panitumumab and irinotecan ver ...... y stratified randomised trial.
@en
Panitumumab and irinotecan ver ...... y stratified randomised trial.
@en-gb
type
label
Panitumumab and irinotecan ver ...... y stratified randomised trial.
@en
Panitumumab and irinotecan ver ...... y stratified randomised trial.
@en-gb
prefLabel
Panitumumab and irinotecan ver ...... y stratified randomised trial.
@en
Panitumumab and irinotecan ver ...... y stratified randomised trial.
@en-gb
P2093
P2860
P1154
2-s2.0-84879786289
P1433
P1476
Panitumumab and irinotecan ver ...... y stratified randomised trial.
@en
P2093
Alfred Oliver
Ann O'Callaghan
Catherine Lowe
Gary Middleton
Jennifer F Seligmann
Jonathan Wadsley
Kim Benstead
Lesley Dawson
P2860
P304
P356
10.1016/S1470-2045(13)70163-3
P5530
P577
2013-05-29T00:00:00Z
P5875
P6179
1025633955